top of page

Zevra Therapeutics Media Release | April 15, 2024

Zevra Therapeutics Presents New Data On The Long-Term Safety And Efficacy Of Arimoclomol As A Treatment For Niemann-Pick Disease Type C At The SIMD 45th Annual Meeting


Read the full statement from Zevra Therapeutics here:



Here is a summary of the article:

 

To join our fight, as well as fund vital research for a cure, support the Australian NPC Disease Foundation in its goals of "Research. Cure. Persevere."


Ways to support NP-C in Australia:



28 views0 comments

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page